

Sector update

Company update

- Alembic Pharma (ADD)
- Alkem Labs (BUY)
- Aurobindo (ADD from Buy)
- Biocon (ADD)
- Cadila Health (HOLD from Buy)
- Cipla (BUY)
- Divis Labs (ADD)
- Dr Reddy's (ADD)
- Glenmark (ADD from Buy)
- JB Chemicals (ADD from Buy)
- Jubilant Life (ADD)
- Lupin (HOLD)
- Natco Pharma (HOLD from Add)
- Shilpa Medicare (HOLD from Add)
- Strides (ADD from Buy)
- Sun Pharma (BUY)
- Torrent Pharma (ADD)
- Abbott India (BUY)
- GSK Pharma (HOLD)
- Pfizer (REDUCE from Hold)
- Sanofi (ADD from Hold)

Research Analysts:

Sriraam Rath

sriraam.rathi@icicisecurities.com
+91 22 6637 7574

Vinay Bafna

vinay.bafna@icicisecurities.com
+91 22 6637 7339

Pharmaceuticals

Outlook 2021: Valuation erating to sustain

We remain positive on the pharma sector for next year as we expect growth in India formulations to revive to 10-11%, cost control measures undertaken during the pandemic to aid profitability, and positive growth in US sales on a corrected base coupled with normalised price erosion. Pharma companies under our coverage witnessed an average 58% growth in stock prices over the past one year largely due to improved profitability and valuation erating given growth visibility. USFDA inspections have been restricted in CY20 due to the pandemic and would resume once the COVID-19 situation normalises. We recommend **BUY** on companies with strong India business and pipeline of complex generics in the US. **Cipla, Alkem and Abbott India are our top picks.**

- ▶ **Outlook for CY21:** We are positive on the sector and expect revenue growth to improve in the coming year. We believe India business would see healthy recovery in growth on the low base of CY20, which has been impacted by COVID-19 led lockdown. We believe ~10% growth is sustainable over the medium term while CY21 may witness higher growth. In the US, companies with clean FDA record and complex generics pipeline are poised to grow with steady improvement in profitability. USFDA inspections were restricted in CY20 owing to travel restrictions caused by the pandemic. We expect these inspections to resume as the situation normalises with an option of implementing desktop audit for quick resumption of the process. Progress on specialty business in the US would be closely monitored as this segment has lagged expectations. API and CRAMS businesses would continue to grow at a healthy pace with India becoming a preferred manufacturing destination.
- ▶ **Key sector trends in CY20:** Key notable trends in pharma were: 1) lack of USFDA inspections at Indian plants as travel restrictions were imposed since Mar-Apr'20 due to the pandemic; 2) weak growth in India formulations, especially in the acute segment as new prescriptions dwindled with low doctor-patient interaction due to the lockdown; 3) strong traction in API business; and 4) cost rationalisation. The sector outperformed the broader market led by growth visibility, profitability improvement led by cost savings, stable pricing in US market, and no major regulatory hurdles. Indian plants received four warning letters in CY20-TD vs 15 in CY19 as the number of inspections was limited this year.
- ▶ **Key expectations in CY21:**
 - Growth recovery in Indian branded pharma market to be >10% vs ~3% in CY20.
 - High number of USFDA inspections once situation normalises since several plants are due for re-inspection.
 - Positive growth in US generic business as price erosion has normalised.
 - Improved profitability and cost-savings undertaken during lockdown would partially sustain.
 - Focus on execution to improve growth and moderation in capex & R&D spend.
- ▶ **Our view:** We continue to prefer companies with higher India sales, complex generic pipeline in the US, and clean FDA status. **Top picks:** Cipla, Alkem Labs, and Abbott India. Rationale: higher India sales, and improving margins and return ratios. Considering the recent run-up in stock price, we downgrade Aurobindo to **ADD** from **Buy**, Cadila to **HOLD** from **Buy**, Glenmark to **ADD** from **Buy**, JB Chemicals to **ADD** from **Buy**, Natco to **HOLD** from **Add**, Pfizer to **REDUCE** from **Hold**, Shilpa Medicare to **HOLD** from **Add** and Strides to **ADD** from **Buy**. Post the recent stock price correction we upgrade Sanofi to **ADD** from **Hold**.
- ▶ **Key risks:** High number of USFDA inspections, currency volatility, and inclusion of more products under NLEM in India.

Valuation summary

	RATING	CMP	TP	M Cap	PE (x)			EV/EBITDA (x)			ROE (%)			RoCE (%)		
		(Rs)	(Rs)	(Rs bn)	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Pharma																
Alembic	Add	1,087	1,151	205	18.8	21.2	20.4	13.3	13.6	12.6	28.3	19.3	17.5	21.0	16.8	15.7
Alkem	Buy	2,896	3,566	346	23.5	22.5	19.9	17.0	16.1	14.1	22.1	19.9	19.6	18.1	17.3	18.1
Aurobindo	Add	897	970	526	16.6	15.5	14.1	10.0	9.4	8.3	17.4	16.0	15.3	13.9	14.4	14.6
Biocon	Add	455	490	546	61.3	38.8	26.4	29.6	20.9	15.2	12.5	17.1	20.9	8.2	11.6	15.5
Cadila	Hold	467	476	478	24.2	22.9	20.3	15.5	14.8	13.2	18.1	17.2	17.5	11.1	11.3	12.3
Cipla	Buy	756	938	609	26.3	23.1	20.2	14.0	12.4	10.6	13.8	13.9	14.0	11.9	12.4	13.0
Divis Labs	Add	3,641	3,960	967	50.1	41.8	35.4	34.7	28.8	24.2	23.9	23.6	23.2	23.0	22.9	22.5
Dr Reddy's	Add	5,016	5,412	832	30.1	26.4	18.0	17.4	15.2	10.6	16.6	16.6	21.0	14.5	14.7	18.8
Glenmark	Add	527	586	149	16.2	15.4	13.5	8.7	8.2	7.3	14.1	13.1	13.2	10.2	10.0	10.4
JB Chemicals	Add	997	1,114	77	21.1	19.2	16.8	13.9	12.5	10.7	22.9	20.6	19.7	21.9	19.9	19.1
Jubilant LifeScience	Add	796	852	124	14.5	12.3	11.0	8.1	7.0	6.2	14.6	15.2	15.0	10.0	10.9	11.3
Lupin	Hold	940	964	426	39.5	25.9	22.2	17.7	13.3	11.5	8.3	11.7	12.4	6.7	10.1	11.0
Natco	Hold	951	974	173	31.1	30.3	14.1	23.0	22.1	10.2	14.0	12.9	24.0	12.8	12.0	22.2
Shilpa Medicare	Hold	475	472	38	23.5	21.6	18.9	16.7	15.8	13.8	11.5	11.1	11.4	9.2	8.8	9.2
Strides Pharma Sci	Add	784	822	70	28.3	18.8	15.8	12.6	10.7	9.3	9.4	12.6	13.3	7.2	9.5	10.2
Sun	Buy	567	652	1,360	27.6	23.5	20.2	16.6	14.3	12.1	10.8	11.9	12.5	8.8	10.1	10.9
Torrent Pharma	Add	2,646	3,014	448	35.9	29.5	24.8	19.4	17.0	14.9	24.1	25.4	26.0	16.3	18.9	21.4
MNC																
Abbott India	Buy	16,006	18,435	340	46.0	39.1	34.2	33.3	28.2	24.4	29.1	29.1	26.6	26.9	27.1	25.1
GSK Pharma	Hold	1,551	1,511	263	51.4	43.9	38.5	34.9	30.1	26.4	26.9	28.5	29.0	23.3	24.9	25.3
Pfizer	Reduce	5,278	4,963	241	48.6	40.1	34.7	31.3	26.8	23.3	17.1	22.5	21.8	16.7	21.8	21.2
Sanofi India (CY er	Add	7,984	8,731	184	32.2	32.3	28.3	22.5	22.8	20.1	24.0	22.9	22.8	23.1	22.1	22.1


Source: Company data, I-Sec research

Prefer companies with India focus and complex generic pipeline for US

We retain our positive view on India branded formulations business and diversified US generic pipeline of complex products (including Para IV / FTFs) with clear FDA status.

- India branded formulations business was affected in CY20 as the populace was confined to their homes and doctor clinics and hospitals were working at lower occupancies due to COVID-19 led lockdown. However, lockdown restrictions have eased in most parts of the country and marketing/promotional activities have normalised. Hence, we expect growth to revert to ~10% in the medium term and CY21 may see an even higher growth on a low base. Industry growth reverted to high single digit in Oct-Nov'20 vs ~3% MAT growth in H1FY21. We expect the double-digit growth (>10% in CY21) to be largely driven by pick-up in acute portfolio, steady growth in chronic segment, ~5% volume growth, price hikes and new product introductions. We believe India business provides sustainability in terms of revenue growth with limited foreseeable threats, and that operating leverage would help improve profitability.
- Consistent launch momentum backed by pipeline of higher number of pending ANDAs along with complex or niche generics are critical for sustaining positive growth momentum in a challenging US environment where competition is constantly increasing. However, price erosion has largely eased and normalised to ~5%.
- Increasing USFDA observations over the past few years have forced companies to become more compliant. Clean FDA status would help companies in maintaining the launch momentum including FTFs and limited-competition products that are time sensitive and any adverse FDA outcome may result in opportunity lost.

Chart 1: Positioning based on India sales, EPS CAGR and US pipeline




Source: Industry data, I-Sec research

Note: 1) **Warning letter/import alert**, **483 observations** and **no ongoing FDA issues**.
2) Bigger size of bubble denotes better pipeline for US.

Relative attractiveness of pharma companies


Based on relative growth and valuations, Alkem, Lupin and Shilpa Medicare look better placed compared to other companies. Natco Pharma is featuring in the bottom half (high relative valuation vs growth) as its current price factors-in the upside expected from generic *Revlimid* opportunity to some extent. However, growth does not capture this as it will be monetised from FY22.

Chart 1: P/E vs EPS CAGR – STR and BIOS look better




Source: Industry data, I-Sec research

Chart 2: EV/EBITDA vs EBITDA CAGR – NTCPH, DRRD and BIOS look better



Source: Industry data, I-Sec research

Chart 3: FCF yield – ARBP, JUBILANT, STR and JBCP look better

Source: Industry data, I-Sec research

Cost control benefits drive earning upgrades

During the pandemic, most companies focused on controlling costs including natural cost savings such as reduction in marketing & promotional activities, travel, etc. Significant EBITDA margin expansion was observed in H1FY21. As per management commentary of various companies, part of the cost savings implemented in H1FY21 would be sustainable on the back of cautious decisions on various cost items and move towards digital activities including marketing. This along with improved growth visibility has led to material earning upgrades.

Table 1: EBITDA margin expansion in H1FY21

Company	H1FY21	H1FY20	change (bps)
Abbott India	22.4	18.4	400
Alembic	30.4	26.0	440
Alkem	26.0	17.4	860
Aurobindo	21.7	20.9	80
Biocon	23.6	27.8	(420)
Cadila	22.5	19.3	320
Cipla	23.7	21.6	210
Divis Labs	41.4	33.6	780
Dr Reddy's	25.1	19.9	520
Glenmark	19.8	15.9	390
GSK Pharma	20.9	21.5	(60)
JB Chemicals	27.5	21.7	580
Jubilant LifeSciences	18.5	20.3	(180)
Lupin	14.5	16.5	(200)
Natco	32.8	33.3	(50)
Pfizer	35.1	29.7	540
Sanofi India (CY ending)	25.0	21.7	330
Shilpa Medicare	26.8	21.5	530
Strides Pharma Science	19.6	19.3	30
Sun	25.0	22.7	230
Torrent Pharma	31.8	26.9	490

Source: Bloomberg, I-Sec research

Table 2: Earning upgrades over past one year

Company	Dec'20		Jan'20		% change	
	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E
Abbott India	347.8	409.6	342.6	401.3	1.5	2.1
Alembic	57.9	51.3	32.3	39.0	79.2	31.5
Alkem	123.3	128.5	100.7	115.3	22.4	11.4
Aurobindo	53.9	57.7	56.7	57.0	(4.9)	1.2
Biocon	7.4	11.7	-	-	-	-
Cadila	19.3	20.4	15.0	18.5	28.3	10.0
Cipla	28.7	32.7	23.0	26.9	24.8	21.4
Divis Labs	72.7	87.1	-	-	-	-
Dr Reddy's	166.8	190.0	127.9	150.1	30.4	26.6
Glenmark	32.5	34.3	28.5	33.5	13.9	2.2
GSK Pharma	30.2	35.3	39.7	46.1	(24.1)	(23.4)
JB Chemicals	47.3	51.9	34.2	39.1	38.4	32.8
Jubilant LifeSciences	54.9	64.7	60.0	68.3	(8.5)	(5.1)
Lupin	23.8	36.3	32.9	42.2	(27.6)	(14.0)
Natco	30.6	31.4	32.6	35.8	(6.4)	(12.5)
Pfizer	108.6	131.5	141.4	163.7	(23.2)	(19.7)
Sanofi India (CY ending)	247.7	247.0	247.8	288.0	(0.0)	(14.2)
Shilpa Medicare	20.2	22.0	17.8	20.6	13.7	6.7
Strides Pharma Science	27.8	41.7	34.6	44.0	(19.9)	(5.2)
Sun	20.5	24.2	21.4	24.4	(3.9)	(1.1)
Torrent Pharma	73.7	89.8	71.1	88.4	3.6	1.5

Source: Bloomberg, I-Sec research

Table 3: Revenue and earnings growth expectations (FY20-FY23, CAGR %)

Company	Revenue	EBITDA	PAT
Abbott India	8.6	17.7	18.8
Alembic	15.8	11.7	5.2
Alkem	9.4	16.3	15.7
Aurobindo	5.5	6.8	8.9
Biocon	20.4	31.6	43.5
Cadila	7.3	11.8	18.3
Cipla	9.9	16.6	23.9
Divis Labs	20.8	28.4	25.7
Dr Reddy's	14.0	27.5	35.5
Glenmark	7.2	12.1	17.9
GSK Pharma	6.7	11.9	12.1
JB Chemicals	11.3	17.8	18.0
Jubilant LifeSciences	6.4	6.4	7.7
Lupin	7.5	17.3	24.4
Natco	20.7	39.8	38.5
Pfizer	9.1	17.4	11.6
Sanofi India (CY ending)	2.1	6.8	12.6
Shilpa Medicare	9.5	13.2	9.5
Strides Pharma Science	13.3	16.2	59.0
Sun	6.8	12.2	19.5
Torrent Pharma	7.6	12.8	23.0

Source: I-Sec research

Valuation rerating to sustain

Sector valuations have rerated in CY20 driven by relatively sustainable growth during pandemic, earning upgrades and stable pricing environment in US. We believe this valuation rerating would continue considering the future growth visibility and tailwinds from potential manufacturing shift from China to India for APIs and likely high growth in India in CY21 on low base.

Table 4: Change in estimates, target price and rating

Company	Change in Revenue (%)			Change in EPS (%)			Target Price (Rs)		Rating	
	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	New	Old	New	Old
Abbott	-	-	-	-	-	-	18,435	18,435	Buy	Buy
Alembic	-	-	-	-	-	-	1,151	1,151	Add	Add
Alkem	-	-	-	-	-	-	3,566	3,566	Buy	Buy
Aurobindo	-	-	-	-	-	-	970	970	Add	Buy
Biocon	-	-	-	-	-	-	490	466	Add	Add
Cadila	-	-	-	-	-	-	476	476	Hold	Buy
Cipla	-	-	-	-	-	-	938	938	Buy	Buy
Divis Labs	-	-	-	-	-	-	3,960	3,960	Add	Add
Dr Reddys	-	-	-	-	-	-	5,412	5,412	Add	Add
Glenmark	-	-	-	-	-	-	586	586	Add	Buy
GSK	-	-	-	-	-	-	1,511	1,511	Hold	Hold
JB Chemicals	-	-	-	-	-	-	1,114	1,114	Add	Buy
Jubilant Life	-	0.6	0.6	-	0.8	0.8	852	806	Add	Add
Lupin	-	-	-	-	-	-	964	964	Hold	Hold
Natco	-	-	-	-	-	-	974	974	Hold	Add
Pfizer	-	-	-	-	-	-	4,963	4,963	Reduce	Hold
Sanofi	-	-	-	-	-	-	8,731	8,731	Add	Hold
Shilpa Med	-	-	-	-	-	-	472	472	Hold	Add
Strides	-	-	-	-	-	-	822	776	Add	Buy
Sun Pharma	-	0.4	0.8	-	2.0	3.1	652	610	Buy	Buy
Torrent	-	-	-	-	-	-	3,014	3,014	Add	Add

Source: I-Sec research

Table 5: Financial summary

	Revenue (Rs m)				EBITDA Margin (%)				Adjusted PAT (Rs m)				EPS (Rs)			
	FY20	FY21E	FY22E	FY23E	FY20	FY21E	FY22E	FY23E	FY20	FY21E	FY22E	FY23E	FY20	FY21E	FY22E	FY23E
Pharma																
Alembic	46,058	56,975	64,615	71,540	26.6	29.3	25.1	23.8	8,375	11,376	10,092	10,481	45.8	57.9	51.3	53.3
Alkem	83,444	90,118	99,355	109,188	17.7	22.4	20.9	21.2	10,957	14,738	15,359	17,435	94.3	123.3	128.5	145.8
Aurobindo	230,985	249,827	255,854	271,310	21.1	21.2	21.2	21.8	28,807	31,610	33,803	37,240	49.1	53.9	57.7	63.5
Biocon	63,672	74,699	92,669	111,059	25.2	25.9	29.3	32.9	6,986	8,910	14,066	20,647	5.8	7.4	11.7	17.2
Cadila	142,019	154,100	163,216	175,227	19.1	21.9	21.3	21.7	14,194	19,740	20,840	23,507	13.9	19.3	20.4	23.0
Cipla	171,320	191,137	208,699	227,100	19.0	22.3	22.3	22.8	15,838	23,178	26,345	30,097	19.6	28.7	32.7	37.3
Divis Labs	53,944	68,654	81,549	95,174	33.8	40.0	40.1	40.5	13,765	19,308	23,109	27,324	51.9	72.7	87.1	102.9
Dr Reddy's	167,371	193,836	212,321	247,718	21.1	24.4	24.9	29.5	25,055	27,682	31,547	46,283	112.0	166.8	190.0	278.8
Glenmark	106,410	110,946	121,405	131,253	16.0	18.9	18.1	18.2	6,713	9,170	9,665	10,999	23.8	32.5	34.3	39.0
JB Chemicals	17,747	19,886	22,138	24,475	21.3	25.7	24.9	25.2	2,799	3,657	4,012	4,594	36.2	47.3	51.9	59.5
Jubilant LifeScienc	91,544	94,872	102,570	110,152	21.3	20.4	21.1	21.3	9,239	8,745	10,314	11,534	58.0	54.9	64.7	72.4
Lupin	152,307	154,120	173,454	189,163	14.5	15.9	18.3	18.9	(104,541)	10,786	16,446	19,149	22.0	23.8	36.3	42.3
Natco	19,150	23,528	23,363	33,638	30.4	30.9	32.1	47.4	4,608	5,561	5,707	12,236	25.3	30.6	31.4	67.2
Shilpa Medicare	9,079	10,257	10,792	11,917	24.2	25.3	26.0	26.7	1,562	1,648	1,795	2,052	19.2	20.2	22.0	25.2
Strides Pharma Sc	27,520	32,665	36,448	39,972	19.4	19.9	20.7	21.0	1,310	2,379	3,734	4,448	12.4	27.8	41.7	49.7
Sun	327,875	338,570	369,189	399,357	21.2	23.2	23.7	24.5	39,410	49,302	57,954	67,225	16.4	20.5	24.2	28.0
Torrent Pharma	79,393	81,099	89,938	98,861	27.3	31.0	31.2	31.5	10,247	12,473	15,195	18,066	57.4	73.7	89.8	106.7
MNC																
Abbott India	40,931	43,457	48,082	52,429	18.5	21.9	22.9	23.5	5,929	7,390	8,704	9,950	279.0	347.8	409.6	468.2
GSK Pharma	32,244	32,510	35,887	39,180	20.4	22.0	22.9	23.5	1,973	5,109	5,982	6,817	28.6	30.2	35.3	40.2
Pfizer	21,517	23,034	25,424	27,943	26.6	31.6	32.6	33.1	4,422	4,968	6,017	6,957	109.3	108.6	131.5	152.1
Sanofi India (CY er	30,706	29,487	29,808	32,662	21.7	25.6	24.5	24.8	4,551	5,697	5,680	6,490	197.9	247.7	247.0	282.2

Source: I-Sec research

Table 6: Latest status of USFDA inspections on Indian facilities


Company	Location	API/Formulations	Last inspection	Status
Alembic	Panelav, Gujarat	Formulations	Mar-20	Cleared
	Panelav, Gujarat	API	Dec-18	Cleared
	Karakhadi, Vadodara, Gujarat	API	Jan-20	Cleared
	Karakhadi, Vadodara, Gujarat (Aleor)	Formulations	Jan-20	Cleared
Alkem	Daman	Formulations	Aug-19	Cleared
	Mandava, Gujarat	API	Sep-15	Cleared
	Ankleshwar, Gujarat	API	Dec-16	Cleared
	Baddi, HP	Formulations	Feb-20	Cleared
	California, US	API	2015	Cleared
	St Louis, Missouri, US	Formulations	Feb-20	Cleared
	Taloja, Maharashtra	R&D	Oct-19	Cleared
Aurobindo	Unit I, Medak, Telangana	API	Feb-19	OAI
	Unit III, Bachupally, Telangana	Formulations	May-19	Ten 483 observations
	Unit IV, Pashamylaram, Telangana	Formulations	Nov-19	Fourteen 483 observations (VAI on 21/4/20)
	Unit V, Patancheru, Hyderabad	Formulations	Aug-19	Four 483 observations (VAI on 9/12/19)
	Unit VI, Chitkul, Telangana	Formulations	Aug-17	Cleared
	Unit VII, Polepally, Telangana	Formulations	Sep-19	Seven 483 observations (OAI in Jan'20)
	Unit VIII, Sangareddy, Telangana	Formulations	Oct-19	Cleared
	Unit IX, Hatnoora, Telangana	API/Intermediates	Jan-19	Five 483 observations (OAI)
	Unit XI, Pydibhimavaram, Srikakulam	API	Feb-19	Three 483 observations (OAI) & WL
	Unit XII, Bachupally, Telangana	Formulations	Jul-15	Cleared
	Unit XVI, Jadcherla, Telangana	Formulations/Injectables	Mar-19	Cleared
Biocon	Malaysia	Formulations/Injectables	Feb-20	Cleared
	Bangalore (2 units)	Formulations	Sep-20	Cleared
	Bangalore (Small Molecule)	API	Jan-20	Cleared
Cadila	Moraiya, Gujarat	API	May-19	Fourteen 483 observations (OAI) & WL
	Ankleshwar, Gujarat	API	Jul-19	Cleared
	Baddi, HP	Formulations	Mar-20	Cleared
	Ahmedabad, Gujarat	Formulations	Dec-19	Cleared
	St Louis, US	Formulations	May-19	Eight 483 observations (VAI)
	Dabhasa, Gujarat	API	Oct-19	Cleared
Cipla	Salcette, Goa	Formulations	Sep-19	Twelve 483 observations (OAI)
	Bengaluru, Karnataka	API	Jul-19	Cleared
	Kurkumbh Village, Maharashtra	API+Formulations	Dec-16	Cleared
	Pithampur, MP	Formulations	Apr-18	Three 483 observations
	Patalganga, Maharashtra	API+Formulations	Nov-19	Cleared
Divis Labs	Unit 2, Chippada, AP	API/CRAMS	Jan-20	Cleared
	Unit 1, Choutuppall, Telangana	API/CRAMS	May-18	Cleared
DRL	Bollaram, Telangana	API	Jul-19	Cleared
	Jeedimetla, Telangana	API	Apr-15	Cleared
	Srikakulam, AP	API	Jan-20	Cleared (VAI) on 8/5/20
	Srikakulam, AP (SEZ)	API	Oct-19	Cleared
	Srikakulam, AP	Formulations	Jan-19	Four 483 observations (VAI)
	Bachupally, Telangana	Formulations	Feb-19	Cleared
	Duvvada, Vizag	Formulations	Aug-19	Eight 483 observations (VAI on 16/2/20)
	Miryalguda, Telangana	API	Mar-20	Cleared
	Bristol, US	Formulations	Jan-15	Cleared
	Shreveport, US	Formulations	Aug-19	Cleared
	Middleburgh, US	API	Oct-17	Cleared
Glenmark	Colvale, Goa	Formulations	Oct-19	Two 483 observations
	Pithampur, MP	Formulations	Aug-17	Cleared
	Baddi, HP	Formulations	Apr-19	WL in Oct'19
	Ankleshwar, Gujarat	API	Oct-18	Cleared
	Dahej, Gujarat	API	Apr-15	Cleared
	Aurangabad, Maharashtra	Formulations	Aug-18	Cleared
	Indiore, MP	Formulations	Sep-19	Cleared

Company	Location	API/Formulations	Last inspection	Status
Lupin	Mandideep, MP (Unit 1)	API+Form	Dec-18	10-API + 8-Form 483 observations (OAI in Mar'19, WL in Sep'19)
	Mandideep, MP (Unit 2)	API	Dec-18	Cleared
	Chikalthana, Maharashtra	Formulations	Feb-20	Cleared
	Salcette, Goa	Formulations	4/7/2017, 2/8/19	Warning Letter and Two 483 observations (OAI)
	Dabhasa, Gujarat	API	Jul-16	Cleared
	Unit II, Indore, MP	Formulations	5/19/2017, 1/25/2019	Warning Letter and Six 483 observations (OAI)
	Unit III, Pithampur, MP	Formulations	Oct-18	Cleared
	Tarapur, Maharashtra	API	Sep-19	Three 483 observations (OAI)
	Wakad, Maharashtra	R&D	Jun-17	Cleared
	Somerset	Formulations	Nov-20	Thirteen 483 observations (OAI from previous inspection)
Natco	Nagpur, Maharashtra	Formulations	Jan-20	Cleared
	Vizag, AP	API	Jan-20	Cleared
	Coral Springs, Florida	Inhalation research	Feb-20	Cleared
	Mehboobnagar, Kothur, Telangana	Formulations	Jun-19	Cleared
	Mekaguda, Telangana	API	Aug-19	Cleared
Shilpa	Manali, Chennai, TN	API	Feb-16	Cleared
	Vizag, AP	Formulations	Mar-20	Cleared
	Raichur (Unit 1&2)	API	Feb-20	Cleared
	Jaldchera, Telangana	Formulations	Feb-20	Warning Letter and Thirteen 483 observations
Strides	Bangalore	Formulations	Jan-20	Cleared
	Beltapharm Milan, Italy	API	May-15	Cleared
	Chennai (JV with Vivimed)/Alathur	Formulations	Aug-19	Cleared
	Puducherry	Formulations	Feb-19	Warning Letter
	Riviera Beach, Florida	Formulations	Dec-19	Cleared
Sun	Panoli, Gujarat	API	Jul-15	Cleared
	Ahmednagar, Maharashtra	API	Jun-15	Cleared
	Halol, Gujarat	Formulations	Aug-18	Six 483 observations (OAI in Mar'20)
	Karkhadi, Gujarat	API+Formulations	May-15	Cleared
	Dadra	Formulations	Mar-19	Eleven 483 observations (VAI)
	Mohali	Formulations	Nov-17	Cleared
	Toansa	API	Dec-12	Warning Letter
	Cranbury, US	Formulations	Mar-17	Cleared
	Detroit, US	Formulations	May-13	Cleared
	Halol, Gujarat (Baska)	Formulations	Feb-19	Cleared
Torrent	Indrad, Mehsana, Gujarat	Formulations	Apr-19	Four 483 observations (OAI in Aug'19)
	Pithampur, MP	Formulations		Cleared
	Dahej, Gujarat	Formulations	Mar-19	Five 483 observations (OAI in Jul'19)


Source: Industry data, I-Sec research

Price charts


Abbott India




Alembic Pharma




Alkem




Aurobindo




Biocon




Cadila




Cipla




Dr Reddy's




Divis Lab




Glenmark




GSK Pharma




JB Chemicals




Jubilant Life




Lupin




Natco Pharma




Pfizer




Sanofi India




Shilpa Medicare




Strides Pharma Science



Sun Pharma



Torrent Pharma



Source: Bloomberg

In case of industry/sector reports or a report containing multiple stocks, the rating/recommendation for a particular stock may be based on the last released stock specific report for that company.

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

*New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return*

ANALYST CERTIFICATION

I/We, **Sriiram Rath, CA; Vinay Bafna, MBA**; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.